DK0850926T3 - Difluorprostaglandinderivater og deres anvendelse - Google Patents

Difluorprostaglandinderivater og deres anvendelse

Info

Publication number: DK0850926T3
Authority: DK; Denmark
Prior art keywords: difluoro; prostaglandin derivatives; group; medicine; preventive
Prior art date: 1996-12-26

Application number

DK97122702T

Other languages

Danish (da)

English (en)

Inventor

Eiichi Shirasawa

Masaaki Kageyama

Tadashi Nakajima

Takashi Nakano

Nobuaki Mori

Hideshi Sasakura

Yasushi Matsumura

Yoshitomi Morizawa

Original Assignee

Santen Pharmaceutical Co Ltd

Asahi Glass Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-26

Filing date

1997-12-22

Publication date

2003-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0850926(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-12-22 Application filed by Santen Pharmaceutical Co Ltd, Asahi Glass Co Ltd filed Critical Santen Pharmaceutical Co Ltd

2003-02-17 Application granted granted Critical

2003-02-17 Publication of DK0850926T3 publication Critical patent/DK0850926T3/da

Links

239000003814 drug Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)

DK97122702T 1996-12-26 1997-12-22 Difluorprostaglandinderivater og deres anvendelse DK0850926T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP34861496		1996-12-26
JP7405497		1997-03-26
JP17247797		1997-06-27

Publications (1)

Publication Number	Publication Date
DK0850926T3 true DK0850926T3 (da)	2003-02-17

Family

ID=27301396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97122702T DK0850926T3 (da)	1996-12-26	1997-12-22	Difluorprostaglandinderivater og deres anvendelse

Country Status (16)

Country	Link
US (2)	US5886035A (ja)
EP (1)	EP0850926B1 (ja)
JP (2)	JP3480549B2 (ja)
KR (1)	KR100526282B1 (ja)
CN (1)	CN1108289C (ja)
AT (1)	ATE225770T1 (ja)
CA (1)	CA2225761C (ja)
DE (2)	DE69716226T2 (ja)
DK (1)	DK0850926T3 (ja)
ES (1)	ES2187719T3 (ja)
FR (1)	FR11C0020I2 (ja)
LU (1)	LU91943I2 (ja)
NL (1)	NL300407I2 (ja)
NO (2)	NO317060B1 (ja)
PT (1)	PT850926E (ja)
TW (1)	TW536534B (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0930296B2 (en) *	1996-09-17	2005-11-02	Asahi Glass Company Ltd.	Fluorinated prostaglandin derivatives and medicines
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
IL143477A (en)	2001-05-31	2009-07-20	Finetech Pharmaceutical Ltd	Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en) *	2000-01-27	2006-06-11	Finetech Pharmaceutical Ltd	Process for the preparation of latanoprost
AU2001228836A1 (en) *	2000-01-28	2001-08-07	Santen Pharmaceutical Co., Ltd.	Novel difluoroprostaglandin derivative
WO2002022131A1 (fr) *	2000-09-13	2002-03-21	Santen Pharmaceutical Co., Ltd.	Collyre
KR101027454B1 (ko) *	2002-08-23	2011-04-06	산텐 세이야꾸 가부시키가이샤	라타노프로스트를 유효 성분으로 하는 안정한 점안액
CA2707067C (en)	2002-09-09	2013-07-16	Santen Pharmaceutical Co., Ltd.	Clear ophthalmic solution comprising latanoprost as active ingredient
DE602004024427D1 (de) *	2003-07-31	2010-01-14	Santen Pharmaceutical Co Ltd	Prostaglandin enthaltendes produkt
JP4902355B2 (ja) *	2003-12-08	2012-03-21	クゥアルコム・インコーポレイテッド	改良されたリンク同期を備えた高速データレートインタフェース
CN102526064A (zh) *	2004-12-09	2012-07-04	参天制药株式会社	含有分子内具有氟原子的***素的制品
JP4753178B2 (ja) *	2004-12-24	2011-08-24	参天製薬株式会社	プロスタグランジンＦ２α誘導体含有製品
KR101396731B1 (ko) *	2005-03-31	2014-05-19	산텐 세이야꾸 가부시키가이샤	프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
JP5100025B2 (ja) *	2005-03-31	2012-12-19	旭硝子株式会社	プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
WO2006112313A1 (ja)	2005-04-13	2006-10-26	Ube Industries, Ltd.	インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
JP2009500315A (ja) *	2005-06-29	2009-01-08	ファイザー・インク	フルオロプロスタグランジンのニトロ誘導体
CN103755737A (zh) *	2006-02-07	2014-04-30	株式会社·R-技术上野	用于制备***素衍生物的方法
WO2007111806A2 (en)	2006-03-23	2007-10-04	Massachusetts Eye And Ear Infirmary	Cyclopentane heptanoic acid compounds for reducing body fat
FR2918891B1 (fr) *	2007-07-20	2009-09-25	Thea Sa Lab	Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (en)	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Method and composition for treating ocular hypertension and glaucoma
KR101628415B1 (ko)	2008-09-04	2016-06-08	산텐 세이야꾸 가부시키가이샤	15,15-디플루오로프로스타글란딘 Ｆ2α 유도체를 유효 성분으로서 함유하는 모발 성장 촉진제
US20110293549A1 (en)	2009-02-03	2011-12-01	Athena Cosmetics, Inc.	Composition, method and kit for enhancing hair
JP2013534222A (ja)	2010-08-02	2013-09-02	ファーマパテントホールディングインコーポレイテッド	毛を増強するための組成物、方法およびキット
EP3378480A1 (en)	2011-01-19	2018-09-26	Topokine Therapeutics, Inc.	Methods and compositions for treating obesity
TW202126308A (zh)	2011-02-04	2021-07-16	日商興和股份有限公司	青光眼治療劑與高眼壓症治療劑
US8426471B1 (en)	2011-12-19	2013-04-23	Topokine Therapeutics, Inc.	Methods and compositions for reducing body fat and adipocytes
US20150011755A1 (en) *	2012-02-07	2015-01-08	Dr. Reddys Laboratories Limited	Amine salts of prostaglandin analogs
EP2857002A4 (en)	2012-05-30	2015-12-09	Asahi Glass Co Ltd	COMPOSITION FOR CAPILLARY GROWTH
SG11201600237YA (en)	2012-11-21	2016-02-26	Topokine Therapeutics Inc	Methods and compositions for locally increasing body fat
NO2753788T3 (ja)	2013-05-10	2018-06-16
US9820993B2 (en)	2013-05-15	2017-11-21	Topokine Therapeutics, Inc.	Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) *	2013-10-11	2016-01-27	天泽恩源（天津）制药有限公司	一种合成他氟前列素的方法
CN103804195B (zh) *	2014-01-26	2016-06-15	天泽恩源（天津）制药有限公司	一种合成他氟前列素的方法
CN103819436A (zh) *	2014-02-21	2014-05-28	天泽恩源（天津）医药技术有限公司	(3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
US10188661B2 (en)	2014-06-27	2019-01-29	Topokine Therapeutics, Inc.	Topical dosage regimen
KR20160116402A (ko)	2015-03-30	2016-10-10	연성정밀화학(주)	타플루프로스트의 제조방법
CN108366984A (zh)	2015-09-22	2018-08-03	灰色视觉公司	用于治疗眼部病症的化合物和组合物
CN107226790A (zh) *	2016-03-25	2017-10-03	苏州朗科生物技术有限公司	一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el)	2016-04-19	2017-05-19	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en)	2016-08-15	2018-02-22	Santen Pharmaceutical Co., Ltd.	Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) *	2017-01-10	2018-07-20	江苏恒瑞医药股份有限公司	一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) *	2017-05-08	2021-01-12	扬子江药业集团有限公司	他氟前列素的制备方法
CN112457277B (zh) *	2020-12-16	2022-06-28	西安国康瑞金制药有限公司	一种他氟***素的制备方法
CN112832150B (zh) *	2021-01-27	2022-06-24	中交第三公路工程局有限公司	一种涵洞通道等立面垂直凿毛装置
CN112851510B (zh) *	2021-01-27	2022-07-19	Ａｇｃ株式会社	他氟前列素的纯化方法
CN116120268A (zh) *	2023-03-06	2023-05-16	南京华威医药科技集团有限公司	一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) *	2023-03-31	2023-07-14	南京华威医药科技集团有限公司	一种他氟前列素中间体异构体杂质及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5166178B1 (en) *	1987-09-18	1998-07-21	R Tech Ueno Ltd	Ocular hypotensive agents
US5510383A (en) *	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) *	1993-08-30	1995-03-14	R Tec Ueno:Kk	生化学的拮抗および疾患処置剤
EP0930296B2 (en) *	1996-09-17	2005-11-02	Asahi Glass Company Ltd.	Fluorinated prostaglandin derivatives and medicines
WO1998021181A2 (en) *	1996-11-12	1998-05-22	Alcon Laboratories, Inc.	15-fluoro prostaglandins as ocular hypotensives

1997
- 1997-12-12 JP JP34334397A patent/JP3480549B2/ja not_active Expired - Lifetime
- 1997-12-17 TW TW086119094A patent/TW536534B/zh not_active IP Right Cessation
- 1997-12-18 US US08/993,017 patent/US5886035A/en not_active Expired - Lifetime
- 1997-12-22 DK DK97122702T patent/DK0850926T3/da active
- 1997-12-22 PT PT97122702T patent/PT850926E/pt unknown
- 1997-12-22 ES ES97122702T patent/ES2187719T3/es not_active Expired - Lifetime
- 1997-12-22 DE DE69716226T patent/DE69716226T2/de not_active Expired - Lifetime
- 1997-12-22 AT AT97122702T patent/ATE225770T1/de active
- 1997-12-22 DE DE122008000050C patent/DE122008000050I2/de active Active
- 1997-12-22 EP EP97122702A patent/EP0850926B1/en not_active Expired - Lifetime
- 1997-12-23 CA CA002225761A patent/CA2225761C/en not_active Expired - Lifetime
- 1997-12-23 NO NO19976085A patent/NO317060B1/no not_active IP Right Cessation
- 1997-12-26 CN CN97126331A patent/CN1108289C/zh not_active Expired - Lifetime
- 1997-12-26 KR KR1019970074620A patent/KR100526282B1/ko not_active IP Right Cessation
1998
- 1998-08-03 US US09/127,804 patent/US5985920A/en not_active Expired - Lifetime
2003
- 2003-07-31 JP JP2003284134A patent/JP3994074B2/ja not_active Expired - Lifetime
2009
- 2009-03-06 NO NO2009006C patent/NO2009006I2/no not_active IP Right Cessation
- 2009-09-02 NL NL300407C patent/NL300407I2/nl unknown
2011
- 2011-06-21 FR FR11C0020C patent/FR11C0020I2/fr active Active
2012
- 2012-02-15 LU LU91943C patent/LU91943I2/fr unknown

Also Published As

Publication number	Publication date
US5886035A (en)	1999-03-23
JP3994074B2 (ja)	2007-10-17
NO2009006I1 (no)	2009-03-16
ATE225770T1 (de)	2002-10-15
CA2225761C (en)	2009-04-21
TW536534B (en)	2003-06-11
DE69716226T2 (de)	2003-06-05
NO976085L (no)	1998-06-29
NL300407I2 (nl)	2010-03-01
JP3480549B2 (ja)	2003-12-22
FR11C0020I1 (ja)	2011-07-29
DE122008000050I1 (de)	2009-01-29
KR19980064718A (ko)	1998-10-07
FR11C0020I2 (fr)	2012-03-16
EP0850926B1 (en)	2002-10-09
JPH1171344A (ja)	1999-03-16
NO976085D0 (no)	1997-12-23
EP0850926A2 (en)	1998-07-01
JP2004002462A (ja)	2004-01-08
DE122008000050I2 (de)	2011-06-16
NO317060B1 (no)	2004-08-02
DE69716226D1 (de)	2002-11-14
NL300407I1 (nl)	2009-11-02
KR100526282B1 (ko)	2006-05-17
NO2009006I2 (no)	2012-03-05
ES2187719T3 (es)	2003-06-16
LU91943I2 (fr)	2012-04-16
US5985920A (en)	1999-11-16
CN1187486A (zh)	1998-07-15
CN1108289C (zh)	2003-05-14
CA2225761A1 (en)	1998-06-26
PT850926E (pt)	2003-02-28
EP0850926A3 (en)	1999-06-16

Publication	Publication Date	Title
DK0850926T3 (da)	2003-02-17	Difluorprostaglandinderivater og deres anvendelse
DK535789A (da)	1990-04-30	Pyrimidindionderivater, fremgangsmaade til fremstilling heraf og antiarytmika omfattende samme
NO971564L (no)	1997-10-06	1,2-difenylpyrrolderivater, deres fremstilling og deres terapeutiske bruk
DK0613894T3 (da)	1999-11-01	N-Heteroaryl-N'-phenylurinstofderivater, fremstilling og anvendelse deraf
PT918776E (pt)	2004-07-30	Sintese total de acilfulvenos antitumorais
DK0474243T3 (da)	1998-12-07	1-methylcarbapenemderivater og fremgangsmåde til fremstilling deraf
DK0508740T3 (da)	1997-10-20	Thiazolidindionderivater, deres fremstilling og anvendelse.
ATE223411T1 (de)	2002-09-15	1-methylcarbapenem-derivate
DE69828197D1 (de)	2005-01-20	Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
FI956151A0 (fi)	1995-12-20	Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia
ATE146481T1 (de)	1997-01-15	Epoxysuccinamidsäurederivat
ATE86117T1 (de)	1993-03-15	Zusammensetzung gegen leberkrankheiten.
ATE122892T1 (de)	1995-06-15	Zusammensetzung gegen katarakt.
ATE71364T1 (de)	1992-01-15	Fluor enthaltende vitamin-d2-derivate.
DE3782229D1 (de)	1992-11-19	Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
DK0638587T3 (da)	1999-11-22	Salmyciner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel